INDSWFTLAB.NS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (9 May 2024 @ 05:25):

Stats
Today's Volume	372 211
Average Volume	1.02M
Market Cap	6.25B
EPS	INR0 ( 2024-02-12 )
Next earnings date	( INR0 ) 2024-05-13
Last Dividend	INR1.000 ( 2011-09-20 )
Next Dividend	INR0 ( N/A )
P/E	14.39
ATR14	INR0.179 (0.17%)

Volume Correlation

Long: -0.04 (neutral)

Short: 0.94 (very strong)

Signal:(55.825) Expect same movement, but be aware

Ind-Swift Laboratories Correlation

10 Most Positive Correlations
PVP.NS	0.827
ICICIPHARM.NS	0.813
KIMS.NS	0.811

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ind-Swift Laboratories Correlation - Currency/Commodity

0.54
( weak )

0.27
( neutral )

0.00
( neutral )

0.21
( neutral )

-0.58
( weak negative )

-0.03
( neutral )

Ind-Swift Laboratories Financials

Annual	2022
Revenue:	INR12.07B
Gross Profit:	INR5.52B (45.70 %)
EPS:	INR8.06

FY	2022
Revenue:	INR12.07B
Gross Profit:	INR5.52B (45.70 %)
EPS:	INR8.06

FY	2022
Revenue:	INR10.39B
Gross Profit:	INR4.28B (41.20 %)
EPS:	INR-0.360

FY	2021
Revenue:	INR8.91B
Gross Profit:	INR3.61B (40.51 %)
EPS:	INR-0.530

Financial Reports:

No articles found.

Ind-Swift Laboratories Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Ind-Swift Laboratories Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 1.760 - low (50.00%) | Divividend Growth Potential Score: 2.46 - No dividend growth expected in the near future

Information

First Dividend	INR1.000	2004-09-23
Last Dividend	INR1.000	2011-09-20
Next Dividend	INR0	N/A
Payout Date	2011-10-26
Next Payout Date	N/A
# dividends	8	--
Total Paid Out	INR9.00	--
Avg. Dividend % Per Year	0.00%	--
Score	1.21	--
Div. Sustainability Score	1.760
Div.Growth Potential Score	2.46
Div. Directional Score	2.11	--

Next Divdend (Est)
(2024-06-27)

INR0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

1.21

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0	0.00%
2019	INR0	0.00%
2020	INR0	0.00%
2021	INR0	0.00%
2022	INR0	0.00%
2023	INR0	0.00%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
TORNTPHARM.NS	Dividend Junior	2023-06-23	Annually	22	0.85%
PFS.NS	Dividend Junior	2023-09-05	Sporadic	14	1.84%
JAYBARMARU.NS	Dividend Junior	2023-09-08	Annually	23	1.48%
DCMSHRIRAM.NS	Dividend Junior	2023-07-18	Semi-Annually	23	1.23%
SKFINDIA.NS	Dividend Junior	2023-06-28	Annually	22	0.93%
MEDICAMEQ.NS	Ex Dividend Junior	2023-09-20	Annually	3	0.02%
GULFOILLUB.NS	Dividend Junior	2023-08-25	Annually	11	2.19%
BBTC.NS	Dividend Junior	2023-09-22	Annually	22	0.08%
PRIMESECU.NS	Dividend Junior	2023-06-06	Sporadic	19	1.83%
KANSAINER.NS	Dividend Knight	2023-05-25	Annually	21	0.49%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0362	1.500	9.28	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.0612	1.500	-0.431	-0.647	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	2.56	1.000	-0.163	-0.163	[3 - 30]
operatingCashFlowPerShareTTM	16.90	2.00	4.37	8.74	[0 - 30]
freeCashFlowPerShareTTM	16.90	2.00	1.552	3.10	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.476	1.000	5.40	5.40	[0.2 - 0.8]
operatingProfitMarginTTM	0.181	1.000	8.37	8.37	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				1.760

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	14.81	1.000	8.60	0	[1 - 100]
returnOnEquityTTM	0.0612	2.50	-0.277	-0.647	[0.1 - 1.5]
freeCashFlowPerShareTTM	16.90	2.00	4.37	3.10	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	16.90	2.00	4.37	8.74	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.462	1.500	-0.254	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0838	1.000	-0.406	0	[0.1 - 0.5]
Total Score				2.46

Ind-Swift Laboratories

Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, alcohol abstinence, and antineoplastic, as well as various products for ADHD symptoms. It provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, Clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide. The company also offers early and late phase drug development, process research and development, contract and API manufacturing, and custom chemicals and synthesis; and analytical development, regulatory support, chemistry, impurity profiling, isolation, discovery, identification and characterization, and project management services. It also exports its products. Ind-Swift Laboratories Limited was founded in 1995 and is based in Manimajra, India.

Realtime updates for Ind-Swift Laboratories [INDSWFTLAB.NS]

Upcoming Earnings Alert

Ind-Swift Laboratories Dividend Information - Ex Dividend Junior

Dividend Commentary

Top 10 dividend Companies for NSE

Dividend Sustainability Score (DSS)

Dividend Growth Score (DGS)